Table 1.
Myositis specific and associated autoantibodies
| Myositis specific antibody | Cutaneous and musculoskeletal features | Other associated features |
|---|---|---|
| ARS antibodies: Anti-Jo-1, PL7, PL12, EJ, OJ, KS, Hu, Zo | Anti-synthetase syndrome: Myositis, mechanics hand, fever, inflammatory arthritis, Raynaud’s phenomenon | ILD |
| Anti-Mi-2α/ Mi-2β | Mild myositis, cutaneous dermatomyositis | Low risk of ILD and malignancy |
| Anti-SRP | Necrotising myositis | Cardiovascular involvement |
| Anti-MDA5 | CADM, Mucocutaneous ulceration, | RP-ILD, vasculopathy |
| TIF1 gamma / NXP-2 | Dermatomyositis | Increased risk of malignancy |
| Anti-HMGCR | Statin-induced necrotizing myopathy | Dysphagia |
| Myositis associated antibody | Cutaneous and musculoskeletal features | Other associated features |
|---|---|---|
| Anti PM-SCL 100/Anti PM-SCL 75 | Raynaud phenomenon, calcinosis | GERD |
| Anti-Ku | Myositis | GERD, serositis |
| Anti-Ro (SSA)/ Anti-La (SSB) | Sjogren’s syndrome | Auto-immune congenital heart block |
| Anti-U1RNP | Mixed connective tissue disease, SLE | ILD, pericarditis |
ARS aminoacyl-tRNA synthetase enzymes; CADM Clinically amyopathic dermatomyositis; HMGCR HMG-CoA reductase; ILD Interstitial lung disease; MDA5 melanoma differentiation associated gene 5; NXP-2 nuclear matrix protein 2; RP-ILD Rapidly progressive interstitial lung disease; SRP signal recognition particle; TIF transcriptional intermediary factor